FOCUS (Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of ADHD in adults. Approximately 450 patients will be randomized in a 1:1:1 ratio to receive solriamfetol (150 mg or 300 mg) or placebo for 6 weeks. The primary endpoint will be change in the Adult ADHD Investigator Symptom Report Scale (AISRS).

Attention Deficit Hyperactivity Disorder (ADHD)

ADHD is a chronic neurobiological and developmental disorder characterized by a persistent pattern of inattention, hyperactivity or impulsivity, that interferes with functioning or development.¹ Impairments in cognition are apparent in attention, planning and problem solving, working memory, and behavioral inhibition.^2,3 An estimated 11.4 million adults in the U.S. are diagnosed with ADHD, and the condition affects an estimated 5% of children and adolescents.^4,5Approximately two-thirds or more of children with ADHD continue to have symptoms and challenges in adulthood.⁶ The total annual societal excess costs associated with adult ADHD in the U.S. have been estimated at $122.8 billion.⁷